RE:RE:RE:RE:RE:RE:Will it be different this year? DJ.. I too dream of that day - and there is so much advantage with Ruvidar to be taken into consideration.
As has been shared here many a time:
TLT-Ruvidar is the first PDT treatment to be in a FDA phase11 trial.
When TLT will negotiate a joint venture with a Big Pharma for the first FDA approved PDT treatment, the selling points for TLT-PDT will be many.
-TLT- PDT can cure patients that Valrubicin, Keytruda, Adstiladrin, CG- Oncology and N803+BCG couldn't cure(FDA approved treatments).
-TLT- PDT cancer treatment has a very high 450 days 37%TR(CR+PR).
-TLT- PDT cancer treatment has no side effects.
-TLT- PDT treatment can cure patients that surgery couldn't cure.
-TLT- PDT cancer treatment can cure patients that Chemotherapy & Radiotherapy couldn't cure.
-TLT- PDT cancer treatment can be adapted to treat many other cancer treatments.
-TLT- PDT treatment can cure patients after only one or two treatments.
- You can also add vaccines to the above...and we're due for news on that front!
Note:
Adstiladrin and N803+BCG did get the FDA-BTD approval with 450 days CR% numbers that are lower than TLT-Ruvidar.
For a Big Pharma being the first will implies to always be one step ahead of other future PDT treatments
All the above will add a huge $value to any Big Pharma deals
Is Roger and company strategizing for the best leverage in negotiating a deal, given the above and not mentioning future trials on GBM and lung for starters?
You're damn right Skippy!